KRAS and cancer: ELI-002 incorporates either two (ELI-002 2P) or seven (ELI-002 7P) KRAS-mutated Amph-peptides and is currently being investigated as a cancer vaccine in patients with solid tumors harboring KRAS mutations (NCT04853017, NCT05726864) [232].